Pfizer Inc.: Drug Recall
Recall #D-0003-2023 · 09/27/2022
Class II: Risk
Recall Details
- Recall Number
- D-0003-2023
- Classification
- Class II
- Product Type
- Drug
- Recalling Firm
- Pfizer Inc.
- Status
- Terminated
- Date Initiated
- 09/27/2022
- Location
- New York, NY, United States
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 103,150 10 mL vials
Reason for Recall
Presence of Particulate Matter: A complaint was received for the presence of a hair in one vial.
Product Description
Aminophylline Injection, USP 250 mg/10 mL (25 mg/mL) 25x10 mL Single-dose vial, Rx only, Distributed by Hospira, Inc. Lake Forest, IL 60045 USA. NDC 0409-5921-16 (vial) 0409-5921-01 (carton)
Distribution Pattern
Distributed in the United States and Puerto Rico.
Other Recalls by Pfizer Inc.
- Class II: Risk 08/04/2025
- Class II: Risk 08/04/2025
- Class II: Risk 07/10/2025
- Class II: Risk 07/10/2025
- Class II: Risk 05/28/2025
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.